Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Foureau is active.

Publication


Featured researches published by David Foureau.


Liver International | 2017

Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance.

Mark W. Russo; Nury Steuerwald; Harry James Norton; William E. Anderson; David Foureau; Naga Chalasani; Robert J. Fontana; Paul B. Watkins; Jose Serrano; Herbert L. Bonkovsky

Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality.


Drug Safety | 2016

Hepatotoxicity Associated with the Use of Anti-TNF-α Agents

Joshua B. French; Maurizio Bonacini; Marwan Ghabril; David Foureau; Herbert L. Bonkovsky

Medications to inhibit the actions of tumour necrosis factor alpha have revolutionized the treatment of several pro-inflammatory autoimmune conditions. Despite their many benefits, several serious side effects exist and adverse reactions do occur from these medications. While many of the medications’ potential adverse effects were anticipated and recognized in clinical trials prior to drug approval, several more rare adverse reactions were recorded in the literature as the popularity, availability and distribution of these medications grew. Of these potential adverse reactions, liver injury, although uncommon, has been observed in some patients. As case reports accrued over time and ultimately case series developed, the link became better established between this family of medicines and various patterns of liver injury. Interestingly, it appears that the majority of cases exhibit an autoimmune hepatitis profile both in serological markers of autoimmune liver disease and in classic autoimmune features seen on hepatic histopathology. Despite the growing evidence of this relationship, the pathogenesis of this reaction remains incompletely understood, but it appears to depend on characteristics of the medications and the genetic composition of the patients; it is likely more complicated than a simple medication class effect. Because of this still incomplete understanding and the infrequency of the occurrence, treatments have also been limited, although it is clear that most patients improve with cessation of the offending agent and, in certain cases, glucocorticoid use. However, more needs to be done in the future to unveil the underlying mechanisms of this adverse reaction.


Cancer Immunology, Immunotherapy | 2014

Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome

David Foureau; Asim Amin; Richard L. White; William E. Anderson; Chase P. Jones; Terry Sarantou; Iain H. McKillop; Jonathan C. Salo


Experimental hematology & oncology | 2018

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Saad Z Usmani; Imran Khan; Christopher Chiu; David Foureau; Lawrence J. Druhan; Katherine Rigby; Tineke Casneuf; A. Kate Sasser


Blood | 2016

Peripheral Immune Profile and Minimal Residual Disease (MRD) Burden Following Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

David Foureau; Qing Zhang; Tammy Cogdill; Adina S Wynn; Nury Steuerwald; Lawrence J. Druhan; Fei Guo; Katherine Rigby; Kyle Madden; James Thomas Symanowski; Belinda R. Avalos; Edward A. Copelan; Saad Z Usmani; Manisha Bhutani


Blood | 2015

Impact of Lenalidomide Maintenance Therapy on Immune Polarization and Activation in Multiple Myeloma

Manisha Bhutani; David Foureau; Tammy Cogdill; Kyle Madden; Qing Zhang; Sarah A Baxter; Lawrence J. Druhan; Nilanjan Ghosh; Belinda R. Avalos; Edward A. Copelan; Saad Z Usmani


Journal of Clinical Oncology | 2018

Relationship of minimal residual disease (MRD) in acute lymphocytic leukemia (ALL) and putative leukemia stem cells (LSCs).

Jonathan M. Gerber; Elizabeth Jandrisevits; Lawrence J. Druhan; Amanda Lance; Andrea E. Price; Virginia Thurston; Jing Ai; Thomas Gregory Knight; Brittany K. Ragon; Mitchell Turner; Edward H. Lipford; Edward A. Copelan; Michael R. Grunwald; Belinda R. Avalos; David Foureau


Clinical Lymphoma, Myeloma & Leukemia | 2017

Case Report: Deep Sustained Response to Daratumumab Associated with T-cell Expansion in a Patient with Heavily Treated Relapsed and Refractory Myeloma

Saad Z Usmani; Imran Khan; Christopher Chiu; David Foureau; Lawrence J. Druhan; Katherine Rigby; Tineke Casneuf; Kate Sasser


Blood | 2016

NF-κb / STAT3 Signaling Pathway Collaboration in Diffuse Large B-Cell Lymphoma (DLBCL) Cell-of-Origin (COO) Subtypes: Resolution of Myeloid Subversion By Standard Induction Chemotherapy

David Foureau; Qing Zhang; Lawrence J. Druhan; Nury Steuerwald; Fei Guo; Elizabeth Jandrisevits; Belinda R. Avalos; Danyu Sun; Ryan Jacobs; Nilanjan Ghosh


Blood | 2016

A Novel Approach to Identify a Putative Leukemia Stem Cell Population in Acute Lymphocytic Leukemia (ALL) and Distinguish Philadelphia Chromosome-Positive ALL from Lymphoid Blast Crisis Chronic Myeloid Leukemia

Jonathan M. Gerber; Lawrence J. Druhan; David Foureau; Elizabeth Jandrisevits; Amanda Lance; Andrea E. Price; Virginia Thurston; Jing Ai; Michael R. Grunwald; Edward H. Lipford; Belinda R. Avalos

Collaboration


Dive into the David Foureau's collaboration.

Top Co-Authors

Avatar

Lawrence J. Druhan

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Belinda R. Avalos

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Nury Steuerwald

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Saad Z Usmani

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Edward A. Copelan

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fei Guo

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Katherine Rigby

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Nilanjan Ghosh

Carolinas Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Qing Zhang

Carolinas Healthcare System

View shared research outputs
Researchain Logo
Decentralizing Knowledge